Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis

Gastroenterology. 2021 Feb;160(3):932-934.e3. doi: 10.1053/j.gastro.2020.10.029. Epub 2020 Oct 21.

Authors

Shrinivas Bishu¹, Joanna Melia², William Sharfman³, Christopher D Lao⁴, Leslie A Fecher⁴, Peter D R Higgins⁵

Affiliations

¹ Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: bishus@med.umich.edu.
² Division of Gastroenterology, Department of Medicine, John's Hopkins University, Baltimore, Maryland.
³ Division of Oncology, Department of Medicine, John's Hopkins University, Baltimore, Maryland.
⁴ Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
⁵ Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.

PMID: 33096100
DOI: 10.1053/j.gastro.2020.10.029

No abstract available

Keywords: Cancer Outcome; Checkpoint Inhibitor Colitis; Immunotherapy; Refractory.

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Colitis / chemically induced
Colitis / diagnosis
Colitis / drug therapy*
Colitis / immunology
Humans
Immune Checkpoint Inhibitors / adverse effects*
Ipilimumab / adverse effects
Male
Neoplasms / drug therapy
Nivolumab / adverse effects
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Retrospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Ipilimumab
Piperidines
Protein Kinase Inhibitors
Pyrimidines
Nivolumab
tofacitinib
pembrolizumab

Grants and funding